17 results about "Nipah virus" patented technology

The present invention is in the field of Nipah virus (NiV) structural protein. Particularly, the invention provides structure based stabilized Nipah virus (NiV) structural protein designing and uses thereof.

The invention discloses a human expression optimized Nipah virus N gene and application thereof in preparation of Nipah pseudovirus, belongs to the technical field of biology, and constructs a segment of Nipah virus N gene sequence optimized by human cell expression codons and constructs a recombinant vector pcDNA3.1-NiV-N-opti. The recombinant vector pcDNA3.1-NiV-N-opti is used as a pseudovirus expression vector, the recombinant vector pcDNA3.1-NiV-N-opti and pseudovirus packaging plasmids are used for preparing the kit for the nipah pseudovirus, the nipah pseudovirus can be efficiently obtained, the titer of the obtained nipah pseudovirus is higher than that of the nipah pseudovirus packaged by an original sequence, and an unexpected technical effect is achieved. Besides, the Nipah pseudovirus has His, Myc and EGFP marks, the preparation effect of the pseudovirus can be visually observed, and the Nipah pseudovirus can be used for Nipah serological diagnosis, virus neutralizing antibody evaluation and the like and has a good application prospect.

This invention belongs to the field of molecular biology detection technology, specifically relating to a Nipah virus (NiV) nucleic acid detection kit combining RT-LAMP and immunochromatography, and its application. This kit combines the high sensitivity and specificity of loop-mediated isothermal amplification (LAMP) technology with the rapid and visual interpretation advantages of immunochromatographic test strips, enabling on-site, rapid, and accurate detection of NiV. The core components of this invention include: a set of specific primers designed for conserved regions of the NiV gene, an optimized RT-LAMP reaction system, and specially treated immunochromatographic test strips for detecting LAMP amplification products. This kit eliminates the need for reverse transcription of RNA virus nucleic acids and expensive thermal cycling equipment. The entire detection process is completed within 20–30 minutes, with a sensitivity of up to 300 copies / μL. This solution combines the high efficiency of RT-LAMP technology with an intuitive, equipment-free detection method, achieving truly rapid and accurate on-site diagnosis of NiV.

The invention discloses application of carfilzomib in preparation of a medicine for preventing and treating Nipah virus, and belongs to the technical field of medicine. The method mainly aims at ubiquitination modification of nipah virus M protein, the carfilzomib is used for inhibiting a host proteasome path, free ubiquitination factors in cells are depleted to achieve the effect of inhibiting ubiquitination of the M protein, then nucleoplasm shuttle of the M protein is inhibited, replication of the nipah virus is inhibited, and the effect is good. At present, most of research and development of virus medicines and vaccines are designed or modified aiming at viruses, a new thought is provided for research and development of medicines and vaccines in the future, and a new application is also provided for Carfilzomib.

This invention provides a polynucleotide encoding the extracellular domain of the Nipah virus G protein, a recombinant human adenovirus type 5 containing the polynucleotide, and the application of the recombinant human adenovirus type 5 in the preparation of a vaccine to prevent Nipah virus disease. The vaccine provided by this invention has good immunogenicity and can effectively and rapidly stimulate humoral and cellular immune responses in BALB / c mice.

Provided herein are (i) messenger ribonucleic acid (mRNA) comprising an open reading frame (ORF) encoding a soluble Nipah virus glycoprotein (soluble NiV-G) fused to a human type I collagen alpha 1 (COL1A1) signal peptide, (ii) an mRNA comprising an ORF encoding the full-length Nipah virus glycoprotein (full-length NiV-G), (iii) an mRNA comprising an ORF encoding the full-length Nipah virus fusion protein (full-length NiV-F), or (iv) an mRNA comprising an ORF encoding full-length NiV-G and an ORF encoding full-length NiV-F, as well as methods for inducing an immune response against Nipah virus by administering an effective amount of the Nipah virus vaccine composition to a subject in need thereof.

The application discloses a PCR chip for monitoring Nipah virus and products and applications thereof, and relates to the technical field of biological detection. The application provides a PCR chip for monitoring Nipah virus, which comprises the following primers and probes: primers and probes for detecting Nipah virus M subtype; and primers and probes for detecting Nipah virus B subtype. The kit has excellent detection capability for Nipah virus M subtype, Nipah virus B subtype and Hendra virus, is high in sensitivity, good in specificity, accurate and reliable in detection result, strong in repeatability, simple in operation and short in time consumption. The kit can simultaneously realize the differentiation of Nipah virus M / B subtypes and the identification of Hendra virus in a single sample, and provides technical support for the rapid identification of Nipah virus and Hendra virus.

The application provides a kit for detecting nipah virus antigen and application thereof, and belongs to the technical field of biotechnology.The kit comprises quantum dot microsphere labeled nipah virus N protein specific antibody, quantum dot microsphere labeled nipah virus G protein specific antibody, loading liquid and detection test paper.The kit can set double detection lines for nipah virus N protein and G protein on the same detection test paper, realize synchronous combined detection of double targets, avoid false negative and missed detection risk caused by antigen expression abundance difference in different infection stages of viruses, different expression time and improper sampling time in single target detection mode, and significantly improve the overall detection rate of samples.The kit is simple in operation, rapid in detection, does not need large and precise instruments, can realize on-site and real-time qualitative and quantitative detection of samples, is suitable for large-scale rapid screening in primary field and epidemic area, and has good practical application value and popularization prospect.

The invention provides a high-throughput screening method of an anti-Nipah virus drug. The method comprises the following steps: firstly, completing drug gradient dilution and planking pretreatment in a BSL-2 laboratory; then carrying out virus infection, cell culture and 72-hour incubation in the BSL-4 core region; the method comprises the following steps: carrying out rapid and low-cost visual preliminary screening on a whole-plate sample through crystal violet dyeing, and selectively carrying out TRIzol LS inactivation treatment on a small amount of potential effective sample supernatant; after the inactivated sample is transferred to a BSL-2 laboratory, the virus copy number is accurately quantified by adopting a qRT-PCR technology, and finally the drug inhibition ratio and the EC50 value are calculated. According to the method, through a staged screening strategy, on the premise of ensuring biological safety, the screening flux is greatly improved, the detection cost is reduced, and a reliable solution is provided for drug screening of high-pathogenicity pathogenic microorganisms.

The invention relates to a Nipah virus and Hendea virus double-antigen vaccine based on a chimpanzee adenovirus vector and application of the Nipah virus and Hendea virus double-antigen vaccine. The double-antigen vaccine is obtained by directionally cloning a human CMV (cytomegalovirus) promoter, codon optimization sequences for coding NiV fusion glycoprotein (F) (NiV F) and HeV attachment glycoprotein (G) (HeV G) and an expression cassette of SV40 to an E1 deletion site of a chimpanzee adenovirus vector, constructing recombinant plasmids, and packaging and processing the recombinant plasmids. According to the present invention, the replication-deficient chimpanzee adenovirus vector is utilized to express the NiV F protein and the HeV G protein, the vaccine aiming at the two viruses is developed, the effect of preventing two diseases through one injection is achieved, and compared with the single-antigen vaccine in the prior art, the double-antigen vaccine of the present invention has great advantages in practicality and economy.

The application discloses application of STM2457 in preparation of medicines for preventing and treating nipah virus, and belongs to the technical field of medicines.The application mainly aims at m6A modification of a host, inhibits methyltransferase activity of METTL3 through STM2457, and then reduces m6A modification of the host to inhibit replication of the nipah virus, and has good effect.At present, most of the researches on virus medicines and vaccines are designed or modified according to the virus itself, the application provides a new idea for future drug research and development and vaccine research, and also provides a new use for STM2457.

The invention discloses application of ixazomib in preparation of a medicine for preventing and treating Nipah virus, and belongs to the technical field of medicine. The method mainly aims at ubiquitination modification of the nipah virus M protein, the host proteasome pathway is inhibited through the ixazomib, free ubiquitination factors in cells are depleted to achieve the effect of inhibiting ubiquitination of the M protein, then nucleoplasm shuttle of the M protein is inhibited, replication of the nipah virus is inhibited, and a good effect is achieved. The ixazomib is used as a nipah virus inhibitor, belongs to a new application of an old medicine, and provides a new application for the ixazomib. And the safety of the ixazomib has no problem, so that the ixazomib can be applied clinically. In addition, at present, most of research and development of virus drugs and vaccine research are designed or modified aiming at viruses, and a new thought is provided for research and development of drugs and vaccines in the future.

The invention provides a monoclonal antibody combination for Nipah virus detection, an AlphaLISA detection method of Nipah virus and a colloidal gold immunochromatography detection method of Nipah virus, and belongs to the technical field of virus detection. According to the invention, hundreds of antigen-specific B cells are separated from immunized mice, and five stably secreted mAbs are obtained. All antibody heavy chains and light chains can specifically recognize the Nipah virus G protein. The detection limit of the AlphaLISA detection method of the NiV-22 / NiV-12 antibody combination is as low as 0.024 ng / mL, which is about 100 times higher than that of the traditional ELISA, and no cross reaction exists in the test of five heterologous virus antigens. The sensitivity of the colloidal gold immunochromatography detection method of the NiV-22 / NiV-12 antibody combination to G protein reaches 1 ng / mL, the detection sensitivity to Nipah virus pseudovirus reaches 945 TU / mL, and no cross reaction exists in the test of five heterologous virus antigens.

The invention relates to an application of Remodelin in preparation of an anti-Nipah virus drug. The Remodelin can inhibit budding of NiV particles and prevent the virus from being copied in host cells; and the Remodelin can inhibit the duplication of NiV and reduce the virus copy number after NiV infection, and can be used as an NiV inhibitor for preventing or treating NVD.

The application discloses application of MY-1B in preparation of medicines for preventing and treating nipah virus, and belongs to the technical field of medicines.The application is mainly directed to m5C modification of a host, and the methyltransferase activity of NSUN2 is inhibited, so that the m5C modification of the host is reduced, and the replication of the nipah virus is inhibited, and good effects are achieved.At present, most of the researches on virus medicines and vaccines are designed or modified according to the virus itself, and the application provides a new idea for future medicine research and development and vaccine research, and also provides a new use for MY-1B.

This invention provides a monoclonal antibody combination for Nipah virus detection, along with an AlphaLISA and colloidal gold immunochromatographic assay for Nipah virus detection, belonging to the field of virus detection technology. This invention isolates hundreds of antigen-specific B cells from immunized mice, obtaining five stably secreted mAbs. All antibody heavy and light chains specifically recognize the Nipah virus G protein. The AlphaLISA assay using the NiV-22 / NiV-12 antibody combination has a detection limit as low as 0.024 ng / mL, approximately 100 times lower than traditional ELISA, and shows no cross-reactivity in the tests of five heterologous viral antigens. The colloidal gold immunochromatographic assay using the NiV-22 / NiV-12 antibody combination achieves a sensitivity of 1 ng / mL for G protein detection and a sensitivity of 945 TU / mL for Nipah virus pseudovirus detection, showing no cross-reactivity in the tests of five heterologous viral antigens.

This invention belongs to the field of virology, specifically relating to a chimeric VSV recombinant virus and its applications; specifically, it discloses a chimeric VSV recombinant virus strain co-expressing NiV G and F proteins, wherein the chimeric VSV recombinant virus strain is rVSV△G / NiVMYGF and rVSV△G / NiVBDGF; based on its complete viral structure, higher immunogenicity and better safety, it can serve as an important viral reserve resource for the effective prevention and control, diagnosis and detection, vaccine preparation and antiviral treatment products of Nipah disease in the future.